Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05896228 · ClinicalTrials.gov registry record · Phase 2

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

A Phase 2 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, sponsored by Benjamin T Diamond, MD.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT05896228: Recruiting Phase 2 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, sponsored by Benjamin T Diamond, MD.

NCT05896228 is a Phase 2 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma that is actively recruiting participants, run by Benjamin T Diamond, MD. The registered enrollment target is 30 participants, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05896228, a Phase 2 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, is actively recruiting participants, sponsored by Benjamin T Diamond, MD.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.

Primary Outcome

The rate of minimal residual disease negativity (MRD-negativity) will be reported as the number of participants achieving MRD-negativity after eight cycles of Iber-KDd combination therapy. MRD-negativity is defined as less than one (\<1) residual cancer cell detected in 100,000 cells assessed.

Conditions Studied

Refractory Multiple Myeloma Relapsed Multiple Myeloma

Interventions

  • DRUG Acetaminophen
  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Iberdomide
  • DRUG Carfilzomib

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-02-20
Est. Completion 2031-03-01
Phase Phase 2
Benjamin T Diamond, MD

1 total trials

What NCT05896228 shows while recruiting

NCT05896228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (37% lower).

The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Acetaminophen is the first listed.

NCT05896228 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT05896228 about?

NCT05896228 is a clinical study titled "Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma". The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments...

What is the current status of trial NCT05896228?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-02-20. Estimated completion is 2031-03-01.

What conditions does trial NCT05896228 study?

This clinical trial studies the following conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma.

What interventions are being tested in trial NCT05896228?

The interventions under investigation include: Acetaminophen (DRUG), Dexamethasone (DRUG), Daratumumab (DRUG), Iberdomide (DRUG), Carfilzomib (DRUG).

Who is sponsoring clinical trial NCT05896228?

This trial is sponsored by Benjamin T Diamond, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05896228 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05896228's enrollment target sits among peer trials

30 43rd of 67 higher than 22 of 67 other Refractory Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05896228

Source: ClinicalTrials.gov NCT05896228, the US trial registry maintained by the National Library of Medicine. NCT05896228 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.